Showing 4161-4170 of 5623 results for "".
- Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meetinghttps://modernod.com/news/graybug-to-present-preclinical-data-for-gb-401-in-primary-open-angle-glaucoma-at-the-2022-arvo-annual-meeting/2480808/Graybug Vision announced a poster presentation of preclinical data for GB-401 in primary open-angle glaucoma (POAG) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting, to be held at the Colorado Convention Center in Denver from May 1-4, 20
- Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meetinghttps://modernod.com/news/visus-therapeutics-announces-new-scientific-data-to-be-presented-during-the-2022-arvo-annual-meeting/2480805/Visus Therapeutics announced that it will present new scientific data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held May 1-4, 2022 in Denver, Colorado. The two presentations will highlight topics on new research findings on Brimochol PF, th
- Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational NOV03 at ASCRShttps://modernod.com/news/bausch-lomb-presents-data-from-first-pivotal-phase-3-trial-of-investigational-nov03-at-ascrs/2480800/Bausch + Lomb and Novaliq announced that data from the first pivotal phase 3 trial (GOBI) of NOV03 (perfluorohexyloctane), which is being investigated as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibom
- Mitochondria Double as Tiny Lenses in the Eyehttps://modernod.com/news/mitochondria-double-as-tiny-lenses-in-the-eye/2480799/A new report by Wired details a study that found that inside mammalian eyes, mitochondria, the organelles that power cells, may serve a second role as microscopic lenses, helping t
- Haag-Streit Launches the Eyestar 900 Anterior Chamber Suitehttps://modernod.com/news/haag-streit-launches-the-eyestar-900-anterior-chamber-suite/2480794/Haag-Streit has announced the launch of the Eyestar 900 Anterior Chamber Suite (AC-Suite) to compliment the Cataract Suite. The AC-Suite is designed to meet the growing demand for improved outcomes in cataract and refractive surgery. The Eyestar 900 is based on swep
- Ziemer Receives FDA Clearance for the FEMTO Z8 NEOhttps://modernod.com/news/ziemer-receives-fda-clearance-for-the-femto-z8-neo/2480792/Ziemer Ophthalmic Systems has received FDA clearance for its latest femtosecond laser, the FEMTO Z8 NEO—the successor of Femtosecond Laser LDV Z8. The FEMTO Z8 NEO provides advanced hardware, as well as new and improved software applications. The newly designed platform offer
- Envision Invites Students Across the Country Who are Blind or Visually Impaired to Prepare for College and Careers with Annual Level Up Technology Camphttps://modernod.com/news/envision-invites-students-across-the-country-who-are-blind-or-visually-impaired-to-prepare-for-college-and-careers-with-annual-level-up-technology-camp/2480791/Envision has opened high school registration for the 2022 Level Up Technology Camp designed to equip students with vision loss with academic, professional and interpersonal skills needed for college and beyond. High school students with vision loss across the United States ar
- Opthea Names Quinton Oswald and Susan Orr, OD, to its Board of Directorshttps://modernod.com/news/opthea-names-quinton-oswald-and-susan-orr-od-to-its-board-of-directors/2480790/Opthea announced the appointment of Quinton Oswald and Susan Orr, OD, to its Board of Directors, effective immediately following election at a General Meeting of Shareholders on April 21st, 2022. Mr. Oswald and Dr. Orr have deep experience leading biotech companies and launching c
- Orasis Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopiahttps://modernod.com/news/orasis-announces-positive-phase-3-topline-results-of-novel-eye-drop-candidate-csf-1-for-the-treatment-of-presbyopia/2480784/Orasis Pharmaceuticals announced that the phase 3 NEAR-1 and NEAR-2 clinical trials, which evaluated the efficacy and safety of CSF-1, its novel eye drop candidate, met their primary and key secondary endpoints. Additional details of these trials will be presented at future medical meet
- Ocuphire Appoints Jay Pepose, MD, PhD, as Chief Medical Advisor and Announces Upcoming Presentations at ASCRS 2022 and Eyeceleratorhttps://modernod.com/news/ocuphire-appoints-jay-pepose-md-phd-as-chief-medical-advisor-and-announces-upcoming-presentations-at-ascrs-2022-and-eyecelerator/2480777/Ocuphire Pharma announced the appointment of Jay Pepose, MD, PhD, as its Chief Medical Advisor. In addition, Dr. Pepose, Dr. Ralph Chu, and Dr. Marguerite McDonald will deliver three presentations on Nyxol at the American Society of Cataract and Refractive Surgery (ASCRS) which will